Order Article Reprints

Gattinger P, Kratzer B, Sehgal ANA, Ohradanova-Repic A, Gebetsberger L, Tajti G, Focke-Tejkl M, Schaar M, Fuhrmann V, Petrowitsch L, et al. Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model. Vaccines. 2024; 12(3):229. https://doi.org/10.3390/vaccines12030229

Gattinger, Pia, Bernhard Kratzer, Al Nasar Ahmed Sehgal, Anna Ohradanova-Repic, Laura Gebetsberger, Gabor Tajti, Margarete Focke-Tejkl, Mirjam Schaar, Verena Fuhrmann, Lukas Petrowitsch, and et al. 2024. "Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model" Vaccines 12, no. 3: 229. https://doi.org/10.3390/vaccines12030229

Gattinger, P., Kratzer, B., Sehgal, A. N. A., Ohradanova-Repic, A., Gebetsberger, L., Tajti, G., Focke-Tejkl, M., Schaar, M., Fuhrmann, V., Petrowitsch, L., Keller, W., Högler, S., Stockinger, H., Pickl, W. F., & Valenta, R. (2024). Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model. Vaccines, 12(3), 229. https://doi.org/10.3390/vaccines12030229